Development and validation of a liquid chromatography-tandem mass spectrometric method for the determination of α-methyltyrosine in human plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 810, Issue 2, 2004, Pages 229-234

  Humphries, David ^a   Ruterbories, Kenneth ^a   Chan, Clark ^b   Narayanan, Rangaraj ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Lilly NUS Ctr Clin Pharmacol P

Author keywords

Validation; Methyltyrosine

Indexed keywords

ACETIC ACID; BODY FLUIDS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACOKINETICS; PRECIPITATION (CHEMICAL); PROTEINS; SODIUM COMPOUNDS;

GRADIENT MIXTURE; HUMAN PLASMA; INTERNAL STANDARDS; METHYLTYROSINE;

AMINO ACIDS;

ALPHA HYDROXYMETHYLTYROSINE; HYDROXYL GROUP; METIROSINE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; ELUTION; FLOW RATE; HEMOCONCENTRATION; HUMAN; INJECTION; MASS SPECTROMETER; PHASE SEPARATION; PRECIPITATION; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; STANDARD; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY; TECHNIQUE; VALIDATION PROCESS;

EID: 4544340099     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-0232(04)00623-3     Document Type: Article

References (19)

1. K. Engelman, E. Jequier, S. Udenfriend, and A. Sjordsman J. Clin. Invest. 47 1968 577
2. M. Larsson, R. Ohman, L. Wallin, J. Walinder, and A. Carlsson J. Neural Transm. 60 1984 115
3. R.N. Brogden, R.C. Heel, T.M. Speight, and G.S. Avery Drugs 21 1981 81
4. A.M. Meaney, and V. O'Keane Life Sci. 71 2002 979
5. M.P. Johnson, and M. Chamberlain Neuropharmacology 43 2002 799
6. U.D. McCann, D.M. Penetar, Y. Shaham, D.R. Thorne, J.C. Gillin, H.C. Sing, and M.A. Thomas Biol. Psych. 31 1992 1082
7. S.M. Plosker, J. Rabinovici, and R.B. Jaffe J. Clin. Endocr. Metab. 73 1991 549
8. R.C. Zimmermann, L. Krahn, G. Klee, P.Y. Lu, S.J. Ory, and S.C. Lin Psychoneuroendology 21 1996 469
9. R.C. Zimmermann, L. Krahn, G. Klee, E.C. Ditkoff, S.J. Ory, and M.V. Sauer J. Soc. Gynecol. Invest. 8 2001 174
10. G.M. Anderson, G.J. Young, D.J. Cohen, K.R. Schlicht, and N. Patel Clin. Chem. 27 1981 775
11. K. Engelman, E. Jequier, S. Udenfriend, and A. Sjordsman J. Clin. Invest. 47 1968 568
12. M. Laruelle, C. D'Souza, R.M. Baldwin, A. Abi-Dargham, S. Kanesm, C.L. Fingado, J.P. Seibyl, M.B. Bowers, D.S. Charney, and R.B. Innis Neuropsychopharmacology 17 1997 162
13. E. Wiederlöv, and T. Lewander Naunyn-Schmeiderberg's Arch. Pharmacol. 304 1978 111
14. M. Gibaldi, and D. Perrier J. Swarbrick Pharmacokinetics vol. 5 1975 Marcel Dekker New York (Chapter 1)
15. G. Gordon, and P. Skett Introduction to Drug Metabolism third ed. 2001 Nelson Thornes Publishers Cheltenham, UK (Chapter 7)
16. W. Ritschel, and G. Kearns fifth ed. J. Graubart Handbook of Basic Pharmacokinetics vol. 1 1999 American Pharmaceutical Association Washington, DC 12 (Chapter 1)
17. C. Polson, P. Sarkar, B. Incledon, V. Raguvaran, and R. Grant J. Chromatogr. B 785 2003 263
18. DFDF Guidance for Industry, Bioanalytcial Method Validation, US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2001.
19. D.J. Anderson, E.G. Green, J.R. Perkins, S. Lowes, J.D. Henion, J. Sauer, J. Burkey, K.J. Ruterbories, and G. Singh Proceedings of the 49th ASMS Conference on Mass Spectrometry and Allied Topics Chicago, IL, USA May 2001